Adherence to Disease-Modifying Drugs in Patients with Multiple Sclerosis: A Consensus Statement from the Middle East MS Advisory Group

REFERENCES

• Al-Sabbagh, A., (2008, June 9). Medication gaps in disease-modifying drug therapy for multiple sclerosis are associated with an increased risk of relapse: Findings from a national managed care database. Poster session 321 presented at the 18th Meeting of the ENS, Poster 321.
   Google Scholar
• Arnason, B. G. (2005). Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis. Journal of Neurology, 252(Suppl. 3), iii28–iii33.
   Google Scholar
• Atkinson, M. J., (2004). Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health and Quality of Life Outcomes, 2, 12.
   PubMedGoogle Scholar
• Bashir, K., (2002). Optimizing immunomodulatory therapy for MS patients. International Journal of MS Care, 4, 3–7.
   Google Scholar
• Bellary, S., & Barnett, A. H. (2006). Inhaled insulin (Exubera): Combining efficacy and convenience. Diabetes & Vascular Disease Research, 3, 179–185.
   Google Scholar
• Brown, M. G., (2007). How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology, 69, 1498–1507.
   PubMed Web of Science ®Google Scholar
• Buhse, M. (2006). Efficacy of EMLA cream to reduce fear and pain associated with interferon beta-1a injection in patients with multiple sclerosis. The Journal of Neuroscience Nursing, 38, 222–226.
   Google Scholar
• Clanet, M., (2004). Interferon beta-1a in relapsing multiple sclerosis: Four-year extension of the European IFNbeta-1a Dose-Comparison Study. Multiple Sclerosis, 10, 139–144.
   PubMed Web of Science ®Google Scholar
• Cohen, B. A. (2006). Adherence to disease-modifying therapy for multiple sclerosis. International Journal of MS Care, 8(Suppl. 1), 32–37.
   Google Scholar
• Cohen, B. A., & Rieckmann, P. (2007). Emerging oral therapies for multiple sclerosis. International Journal of Clinical Practice, 61, 1922–1930.
   PubMed Web of Science ®Google Scholar
• Conlin, P. R., (2001). Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clinical Therapeutics, 23, 1999–2010.
   PubMed Web of Science ®Google Scholar
• Cooper, I. M. (1996). Morphine for postoperative analgesia. A comparison of intramuscular and subcutaneous routes of administration. Anaesthesia and Intensive Care, 24, 574–578.
   PubMedGoogle Scholar
• Costello, K., (2008). Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape Journal of Medicine, 10, 225.
   PubMedGoogle Scholar
• Cox, D., & Stone, J. (2006). Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. The Journal of Neuroscience Nursing, 38, 167–171.
   PubMedGoogle Scholar
• Cramer, J. A., (2006). Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurologica Scandinavica, 113, 156–162.
   PubMed Web of Science ®Google Scholar
• Dupclay, L., Jr., & Doyle, J. (2002). Assessment of intranasal corticosteroid use in allergic rhinitis: Benefits, costs, and patient preferences. The American Journal of Managed Care, 8, S335–S340.
   PubMed Web of Science ®Google Scholar
• Fallowfield, L., (2006). Patients’ preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer. Annals of Oncology, 17, 205–210.
   PubMed Web of Science ®Google Scholar
• Freedman, M. S., (2004). Treatment optimization in multiple sclerosis. The Canadian Journal of Neurological Sciences, 31, 157–168.
   PubMed Web of Science ®Google Scholar
• Haynes, R. B., Yao, X., Degani, A., Kripalani, S., Garg, A., McDonald, H. P. (2005). Interventions to enhance medication adherence. Cochrane Database Systematic Reviews, CD000011.
   Google Scholar
• Hutchinson, M. (2005). Treatment adherence: What is the best that can be achieved? International MS Journal, 12, 73.
   Google Scholar
• IFNB MS Study Group. (1995). Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology, 45, 1277–1285.
   PubMed Web of Science ®Google Scholar
• Johnson, K. P., (2000). Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Mmultiple Ssclerosis Sstudy Ggroup. Multiple Sclerosis, 6, 255–266.
   PubMed Web of Science ®Google Scholar
• Jordy, S. S., (2008). Immunomodulator therapy migration in relapsing remitting multiple sclerosis: A study of 152 cases. Arquivos de Neuro-Psiquiatria, 66, 11–14.
   Google Scholar
• Kappos, L., (2006). Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology, 67, 944–953.
   PubMed Web of Science ®Google Scholar
• Kruk, M. E., & Schwalbe, N. (2006). The relation between intermittent dosing and adherence: Preliminary insights. Clinical Therapeutics, 28, 1989–1995.
   PubMed Web of Science ®Google Scholar
• Lee, W. C., (2006). Prevalence and economic consequences of medication adherence in diabetes: A systematic literature review. Managed Care Interface, 19, 31–41.
   PubMedGoogle Scholar
• Liu, G., (1997). Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology, 15, 110–115.
   PubMed Web of Science ®Google Scholar
• Lugaresi, A., (2008). Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: The CoSa study. Clinical Neuropharmacology, 31, 167–172.
   PubMed Web of Science ®Google Scholar
• Meletiche, D., (2008a, June 9). Association between adherence with multiple sclerosis disease-modifying therapy and severe relapses using 3 measures of medication adherence. Poster session 717 presented at the 18th Meeting of the ENS.
   Google Scholar
• Meletiche, D., (2008b, June 10). Relationship between severe relapses and adherence to disease-modifying therapy in multiple sclerosis patients. Poster session 826 presented at the 18th Meeting of the ENS.
   Google Scholar
• Milanese, C., (2003). A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: Different response in drop-outs and treated patients. Journal of Neurology, Neurosurgery, and Psychiatry, 74, 1689–1692.
   PubMed Web of Science ®Google Scholar
• Mohr, D. C., (1996). Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: Relationship to adherence to treatment. Multiple Sclerosis, 2, 222–226.
   PubMedGoogle Scholar
• Mohr, D. C., (1999). Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Multiple Sclerosis, 5, 192–197.
   PubMed Web of Science ®Google Scholar
• Mohr, D. C., (2001). Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine, 23, 125–132.
   PubMed Web of Science ®Google Scholar
• Mohr, D. C., (2002). Teaching patients to self-inject: Pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications. Journal of Behavior Therapy and Experimental Psychiatry, 33, 39–47.
   PubMed Web of Science ®Google Scholar
• O’Rourke, K. E., & Hutchinson, M. (2005). Stopping beta-interferon therapy in multiple sclerosis: An analysis of stopping patterns. Multiple Sclerosis, 11, 46–50.
   PubMed Web of Science ®Google Scholar
• Partridge, A. H., (2002). Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute, 94, 652–661.
   PubMed Web of Science ®Google Scholar
• Patten, S. B., (2005). The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Multiple Sclerosis, 11, 175–181.
   PubMed Web of Science ®Google Scholar
• Portaccio, E., (2008). Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. European Neurology, 59, 131–135.
   PubMed Web of Science ®Google Scholar
• Reginster, J. Y., (2006). Adherence, patient preference and dosing frequency: Understanding the relationship. Bone, 38, S2–S6.
   PubMed Web of Science ®Google Scholar
• Rio, J., (2005). Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis, 11, 306–309.
   PubMed Web of Science ®Google Scholar
• Rovaris, M., (2006). Secondary progressive multiple sclerosis: Current knowledge and future challenges. Lancet Neurology, 5, 343–354.
   PubMed Web of Science ®Google Scholar
• Sokol, M. C., (2005). Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care, 43, 521– 530.
   PubMed Web of Science ®Google Scholar
• Stone, V. E. (2001). Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. Clinical Infectious Diseases, 33, 865–872.
   PubMed Web of Science ®Google Scholar
• Tremlett, H. L., & Oger, J. (2003). Interrupted therapy: Stopping and switching of the beta-interferons prescribed for MS. Neurology, 61, 551–554.
   PubMed Web of Science ®Google Scholar
• Williams, M., (2007). The mean levels of adherence and factors contributing to non-adherence in patients on highly active antiretroviral therapy. The West Indian Medical Journal, 56, 270–274.
   PubMedGoogle Scholar
• Wilson, D. M., (1985). Subcutaneous versus intramuscular growth hormone therapy: Growth and acute somatomedin response. Pediatrics, 76, 361–364.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2003). Adherence to Long-term Therapies. Evidence for Action. Geneva.
   Google Scholar